Rokote Laboratories Finland Oy
Rokote Laboratories Finland Oy is a Finnish vaccine development company established in 2020, focusing on developing innovative vaccines including a nasal COVID-19 vaccine. The company collaborates with universities and has received significant funding to advance its vaccine research, aiming to contribute to global health security and vaccine self-sufficiency. It is actively developing a nasal COVID-19 vaccine that aims to provide sterilizing immunity at the virus's entry point, with ongoing clinical trials and a focus on rapid response to virus variants and future pandemics.
Industries
Nr. of Employees
small (1-50)
Rokote Laboratories Finland Oy
Products
Second-generation intranasal adenoviral vector vaccine candidate
A nasally administered adenoviral vector vaccine candidate designed to induce both mucosal (nasopharyngeal IgA) and systemic (serum IgG) immunity, with an antigen sequence updated to improve coverage against circulating viral variants and adaptable for future pathogens.
Second-generation intranasal adenoviral vector vaccine candidate
A nasally administered adenoviral vector vaccine candidate designed to induce both mucosal (nasopharyngeal IgA) and systemic (serum IgG) immunity, with an antigen sequence updated to improve coverage against circulating viral variants and adaptable for future pathogens.
Services
End-to-end design and conduct of first-in-human nasal vaccine studies including protocol development, dose and administration route assessment (spray vs drops), participant screening, safety monitoring, biological sample collection (serum and mucosal), and integration of remote ePRO data.
Process development, transfer and coordination of GMP clinical manufacturing with CMOs including MVSS management, batch production oversight and release readiness activities.
Preparation of clinical trial dossiers and regulatory submission materials for national authority and ethics review; advisory support for quality systems and regulatory interactions.
End-to-end design and conduct of first-in-human nasal vaccine studies including protocol development, dose and administration route assessment (spray vs drops), participant screening, safety monitoring, biological sample collection (serum and mucosal), and integration of remote ePRO data.
Process development, transfer and coordination of GMP clinical manufacturing with CMOs including MVSS management, batch production oversight and release readiness activities.
Preparation of clinical trial dossiers and regulatory submission materials for national authority and ethics review; advisory support for quality systems and regulatory interactions.
Expertise Areas
- Vector-based vaccine design (adenoviral)
- Intranasal / mucosal vaccine delivery
- Preclinical and translational evaluation
- Phase I clinical trial conduct and operational design
Key Technologies
- Adenoviral vector platform
- Intranasal mucosal delivery (spray / drops)
- Master viral seed stock (MVSS) and -80 °C cryostorage
- GMP clinical-scale biologics manufacturing
News & Updates
Rokote Laboratories Finland Oy is starting the first clinical drug trial with its nasal COVID-19 vaccine. The vaccine has been developed and manufactured in Finland, and the study will be conducted at Kuopio University Hospital starting January 21, 2025.
The company has successfully progressed to the stage of submitting an application for its first clinical trial of a nasal COVID-19 vaccine, based on research and preclinical data.
Erkko Ylösmäki has been appointed as the new CEO starting January 1, 2024, with plans to initiate clinical trials by the end of summer 2024.
Professor Seppo Ylä-Herttuala was honored for his contributions to gene therapy, which also support the company's vaccine development efforts.
CEO Tuija Keinonen will present on nasal vaccination strategies at the event in Barcelona, emphasizing the company's innovative approach.
The company has advanced to GMP manufacturing, preparing for clinical trials, with a focus on high-quality, safe vaccine production.
Rokote Laboratories Finland Oy is starting the first clinical drug trial with its nasal COVID-19 vaccine. The vaccine has been developed and manufactured in Finland, and the study will be conducted at Kuopio University Hospital starting January 21, 2025.
The company has successfully progressed to the stage of submitting an application for its first clinical trial of a nasal COVID-19 vaccine, based on research and preclinical data.
Erkko Ylösmäki has been appointed as the new CEO starting January 1, 2024, with plans to initiate clinical trials by the end of summer 2024.
Professor Seppo Ylä-Herttuala was honored for his contributions to gene therapy, which also support the company's vaccine development efforts.
CEO Tuija Keinonen will present on nasal vaccination strategies at the event in Barcelona, emphasizing the company's innovative approach.
The company has advanced to GMP manufacturing, preparing for clinical trials, with a focus on high-quality, safe vaccine production.